DEFA14A: PHIO Pharma Corrects Incentive Plan Share Count

Phio Pharmaceuticals Corp. issued a proxy supplement to correct a scrivener's error regarding the total number of shares reserved for its Long Term Incentive Plan.

Summary

• Phio Pharmaceuticals Corp. filed a supplement to its definitive proxy materials dated July 30, 2025, for the Annual Meeting of Stockholders on September 11, 2025.
• The purpose of the supplement is to correct a scrivener's error in Proposal No. 3, which pertains to an amendment and restatement of the 2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan.
• The aggregate maximum number of shares of Common Stock reserved for issuance under the Plan, if Proposal No. 3 is approved, will be 1,023,017 shares, not the previously reported 950,891 shares.
• This corrected total of 1,023,017 shares comprises: 950,000 shares added by Proposal No. 3, 71,000 shares subject to outstanding RSUs, 1,126 shares subject to outstanding stock options, and 891 shares that remained available for issuance as of the Record Date.
• All references to 950,891 shares in the original Proxy Statement are replaced with 1,023,017 shares.
• All other information in the Proxy Statement remains unchanged.

Sentiment

Score: 5

Explanation: The filing corrects a scrivener's error in a previously issued proxy statement, which is a neutral administrative update. While an error occurred, its prompt correction maintains transparency.

Positives

• The company demonstrated transparency by promptly correcting a material error in its proxy statement.
• Clarification of the total shares available for the Long Term Incentive Plan provides accurate information to stockholders regarding potential future dilution.

Negatives

• The initial occurrence of a scrivener's error in a definitive proxy statement indicates a minor administrative oversight.

Risks

• No specific risks were detailed in this supplementary filing beyond the initial administrative error.

Future Outlook

The filing primarily addresses a past error and does not provide new forward-looking statements or guidance beyond the pending stockholder vote on Proposal No. 3 for the Long Term Incentive Plan.

Management Comments

• The Company discovered a scrivener's error in the aggregate maximum number of shares of Common Stock that will be reserved for issuance under the Plan.

Industry Context

This administrative correction is specific to Phio Pharmaceuticals Corp.'s corporate governance and equity compensation plan and does not reflect broader industry trends or competitive dynamics.

Comparison to Industry Standards

• N/A This filing is an administrative correction to a proxy statement and does not contain performance results or strategic initiatives that can be benchmarked against industry standards or comparable companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides accurate information regarding the potential dilution from the Long Term Incentive Plan, which is slightly higher than initially reported but clarifies the total pool of shares.

Next Steps

• Stockholders are encouraged to vote on Proposal No. 3 at the Annual Meeting on September 11, 2025, considering the corrected share count for the Long Term Incentive Plan.

Key Dates

Recommendation

The filing is an administrative correction to a previously disclosed proxy statement regarding the number of shares reserved for an incentive plan. It does not contain new financial performance data, strategic shifts, or other material information that would warrant a change in investment recommendation. The correction itself is unlikely to significantly impact the company's valuation.

Keywords

PHIO Pharmaceuticals, Long Term Incentive Plan, proxy statement, share count, equity compensation, stock options, RSUs, corporate governance